Life sciences

PsyBio Announces Second Quarter Financial Results of Leo Acquisition Corp.

Tuesday, March 2, 2021 - 3:03am

TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) ( TSXV:PSYB ) (PsyBio), a biotechnology company developing a new class of drugs intended for the treatment of mental health challenges and other disorders, announces the unaudited financial results of Leo Acquisition Corp. (now PsyBio Therapeutics Corp.) for the six month period ended December 31, 2020.

Key Points: 
  • TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- PsyBio Therapeutics Corp. (formerly Leo Acquisitions Corp.) ( TSXV:PSYB ) (PsyBio), a biotechnology company developing a new class of drugs intended for the treatment of mental health challenges and other disorders, announces the unaudited financial results of Leo Acquisition Corp. (now PsyBio Therapeutics Corp.) for the six month period ended December 31, 2020.
  • PsyBio is a US-based biotechnology company developing a new class of drugs intended for the potential treatment of mental health challenges and other disorders.
  • Therefore, actual results may differ materially from what is expressed, implied or forecasted in such forward-looking statements.
  • Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date.

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Reminds AstraZeneca (AZN) Investors of Pending Securities Class Action, Encourages Investors Who Suffered Losses to Contact the Firm

Monday, March 1, 2021 - 10:35pm

SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now.

Key Points: 
  • SAN FRANCISCO, March 01, 2021 (GLOBE NEWSWIRE) -- Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now.
  • A securities fraud class action has been filed and certain investors may have valuable claims.
  • In one trial, patents received a half dose followed by a full dose (resulting in 90% efficacy).
  • Hagens Berman is a national law firm with eight offices in eight cities around the country and over eighty attorneys.

Morphic Therapeutic Announces Proposed Public Offering

Monday, March 1, 2021 - 9:01pm

In addition, Morphic intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock.

Key Points: 
  • In addition, Morphic intends to grant the underwriters a 30-day option to purchase up to an additional $30.0 million of shares of its common stock.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Jefferies, Cowen, BMO Capital Markets and RBC Capital Markets are acting as joint bookrunners for the offering.
  • Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer.

Bristol Myers Squibb Announces Dividend

Monday, March 1, 2021 - 9:16pm

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of forty-nine cents ($0.49) per share on the $.10 par value common stock of the company.
  • The dividend is payable on May 3, 2021 to stockholders of record at the close of business on April 1, 2021.
  • Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
  • For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn , Twitter , YouTube , Facebook , and Instagram .

Geron to Announce Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

Monday, March 1, 2021 - 9:45pm

Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Companys website at www.geron.com/investors .

Key Points: 
  • Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2020 financial results after the market closes on Thursday, March 11, 2021 via press release, which will be available on the Companys website at www.geron.com/investors .
  • Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m.
  • Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.
  • The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.

Penn Wharton Budget Model Projects 3 Million COVID-19 Vaccinations Per Day Would Add 2 Million Jobs, Increase Real GDP By 1 Percent

Monday, March 1, 2021 - 8:20pm

Doubling the number of vaccine doses administered daily to 3 million per day would boost employment by adding 2 million jobs and increase real GDP by about 1 percent over the summer, with smaller effects later in the year.

Key Points: 
  • Doubling the number of vaccine doses administered daily to 3 million per day would boost employment by adding 2 million jobs and increase real GDP by about 1 percent over the summer, with smaller effects later in the year.
  • However, doubling the pace of vaccinations to 3 million per day would prevent a total of about 2 million cases in 2021.
  • Each year 13,000 professionals from around the world advance their careers through Wharton Executive Education's individual, company-customized, and online programs.
  • More than 99,000 Wharton alumni form a powerful global network of leaders who transform business every day.

Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

Monday, March 1, 2021 - 8:02pm

NEW YORK, March 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company , is pleased to announceit has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema .

Key Points: 
  • NEW YORK, March 1, 2021 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company , is pleased to announceit has completed recruitment of Cohort 1 for its upcoming first in human clinical trial of the proprietary BioLexa platform to treat atopic dermatitis, also known as eczema .
  • We are continuing our mission to bring patient focused therapies to the clinic and improve quality of life across multiple indications."
  • Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.
  • Hoth has also entered into two different agreements to further the development of two therapeutic prospects to prevent or treat COVID-19.

Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference

Monday, March 1, 2021 - 8:45pm

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Cowen 41st Annual Health Care Conference, which will take place virtually on March 1-4, 2021.

Key Points: 
  • CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced that the Company will be participating in the Cowen 41st Annual Health Care Conference, which will take place virtually on March 1-4, 2021.
  • Robert Ang, MBBS, MBA, Vors President and Chief Executive Officer, and Nathan Jorgensen, PhD, Chief Financial Officer, are scheduled to present on Thursday, March 4, 2021, at 1:30 p.m. E.T.
  • Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the potential of targeted therapies.
  • By removing biologically redundant proteins from eHSCs, we design these cells and their progeny to be treatment-resistant to complementary targeted therapies, thereby enabling these therapies to selectively destroy cancerous cells while sparing healthy cells.

Adverum Announces Shortened Timelines and Clear Development Path for ADVM-022 Intravitreal Gene Therapy in Wet AMD, Reports Recent Business Progress and Fourth Quarter 2020 Financial Results

Monday, March 1, 2021 - 9:00pm

The Company also reported financial results for the fourth quarter ended December 31, 2020, and provided a business update.

Key Points: 
  • The Company also reported financial results for the fourth quarter ended December 31, 2020, and provided a business update.
  • Pending successful outcomes of these trials, Adverum anticipates being able to submit its Biologics License Application for ADVM-022 for wet AMD in 2024.
  • Stock-based compensation expense included in research and development expenses was $2.2 million for the fourth quarter of 2020.
  • Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases.

GenXys HealthCare Systems announces completion of oversubscribed seed round financing to enable continued market penetration with acclaimed precision prescribing software

Monday, March 1, 2021 - 7:00pm

GenXys provides evidence-based medication decision support tools with embedded pharmacogenetics to enable precision prescribing seamlessly at the point of care.

Key Points: 
  • GenXys provides evidence-based medication decision support tools with embedded pharmacogenetics to enable precision prescribing seamlessly at the point of care.
  • The award-winning suite of clinical decision support software including TreatGx and ReviewGx is now interoperable with electronic health record systems and is pharmacogenetic test agnostic.
  • GenXys, with global headquarters in Vancouver Canada, provides the world's most comprehensive precision prescribing solutions with embedded pharmacogenetics to solve one of healthcare's biggest challenges; inappropriate ("trial-and-error") prescribing.
  • Their clinical decision support software suite is in use by major insurance providers, health systems and pharmacies across North America.